EXICURE, INC. Defined Contribution Plan, Cost
EXICURE, INC. (XCUR) reported Defined Contribution Plan, Cost of $37.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2025-03-18
- EXICURE, INC. defined contribution plan, cost for fiscal 2024 was $37.00K, a 68.91% decline from fiscal 2023.
- EXICURE, INC. defined contribution plan, cost for fiscal 2023 was $119.00K, a 56.88% decline from fiscal 2022.
- EXICURE, INC. defined contribution plan, cost for fiscal 2022 was $276.00K, a 31.34% decline from fiscal 2021.
- EXICURE, INC. defined contribution plan, cost for fiscal 2021 was $402.00K, a 56.42% increase from fiscal 2020.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2024-12-31 | $37.00K 10-K · filed 2025-03-18 |
| 2023-12-31 | $119.00K 10-K · filed 2025-03-18 |
| 2022-12-31 | $276.00K 10-K · filed 2024-06-06 |
| 2021-12-31 | $402.00K 10-K · filed 2023-03-27 |
| 2020-12-31 | $257.00K 10-K · filed 2022-03-25 |
| 2019-12-31 | $185.00K 10-K · filed 2021-03-11 |
| 2018-12-31 | $107.00K 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |